WuXi Biologics signs lease for a clinical manufacturing facility in the US

The deal represents the contract manufacturer's third US site.

The new clinical manufacturing facility will install in total 6000-L bioreactors, process development, quality control laboratories, along with supporting functions. The 66,000-sq. ft facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.

This news follows WuXi Biologics' recent purchase of land to build a new 107,000-sq. ft clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-sq. ft site to establish a process development laboratory in King of Prussia, Pennsylvania.

"We are excited to announce our third site in the US and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries, and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr Chris Chen, CEO of WuXi Biologics.